Study M897
Study name | Savitz J 2020 |
Title | Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid |
Overall design | The aims of this study were to determine the effects of behavioral activation therapy on serum levels of kynurenine pathway metabolites, and to determine whether kynurenine pathway metabolites predicted treatment response. Serum samples were provided by 56 depressed individuals before behavioral activation therapy and 29 of these individuals also provided samples after 10 weeks of group-based behavioral activation therapy to measure kynurenine pathway metabolites. Serum concentrations of tryptophan, kynurenine, kynurenic acid, 3-hydroxykynurenine, and quinolinic acid were determined by high-performance liquid chromatography with tandem mass spectrometry. |
Study Type | Type2; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive symptom; Depressive symptom; Depressive symptom; |
Criteria for depression | Patient Health Questionnaire-9 scores > 9 |
Sample size | 56 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: not reported; |
PMID | |
DOI | |
Citation | Savitz J, Ford BN, Yeh HW, et al. Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid. Psychol Med. 2020 Nov 25:1-10. |
Metabolite |
